TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32311455
Drug: Paracetamol (aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (aqueous solution or suspension)
Study: 32311455
Drug: Danazol (aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (aqueous suspension)
Study: 32311455
Drug: Long-chain triglyceride
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-chain triglyceride solution of danazol
Study: 36189651
Drug: Polynucleotide and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polynucleotide and hyaluronic acid-based gel
Study: 34479364
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants (DOACs) such as apixaban, edoxaban, and rivaroxaban
Study: 33901518
Drug: Low birthweight
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low birthweight (<2500 g)
Study: 33657912
Drug: Information Prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information Prescription (IP) prescribed by the physician plus routine oral information
Study: 33657912
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral information by nurse or physician (control group)
Study: 32351061
Drug: Phlogenzym (systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlogenzym (systemic enzyme therapy)
Study: 33783102
Drug: Negative-pressure wound
Normalized name: Microcyn Negative-Pressure Wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative-pressure wound therapy with instillation (NPWTi)
Study: 32593287
Drug: HFNC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFNC with oxygen flow rate at 40 L/min
Study: 32593287
Drug: HFNC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFNC with oxygen flow rate at 60 L/min
Study: 32593287
Drug: HFNC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFNC with oxygen flow rate at 40 L/min or 60 L/min
Study: 34348343
Drug: Chitosan nanoparticle
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan nanoparticle and gum (CN-G) applied twice daily for 4 weeks
Study: 34348343
Drug: Placebo (gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (gum alone) applied twice daily for 4 weeks
Study: 35583555
Drug: Venetoclax (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (800 mg orally daily) plus Fulvestrant (500 mg intramuscular; cycle 1: days 1 and 15; subsequent 28-day cycles: day 1)
Study: 34937507
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficiency (25(OH)D < 10 ng/ml)
Study: 36007881
Drug: Creatine Monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine Monohydrate (5 g/day)
Study: 36007881
Drug: Creatyl-L-Leucine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatyl-L-Leucine (5 g/day)
Study: 35793342
Drug: Melatonin supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin supplement
Study: 35793342
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of physical exercise and melatonin supplement
Study: 33773532
Drug: Routine chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine chemotherapy care (control group)
Study: 34473402
Drug: Daily PrEP
Normalized name: Zinc Oxide 238 mg in 1 mL / Titanium Dioxide 41 mg in 1 mL TOPICAL LOTION [bareMinerals Prep Step Mineral Shield Broad Spectrum SPF 50 Daily Prep]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily PrEP regimen (TDF/FTC 300 mg/200 mg)
Study: 34473402
Drug: On-demand PrEP
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand PrEP regimen (TDF/FTC 300 mg/200 mg)
Study: 34269239
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (BCP and xenograft)
Study: 33357325
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention including inpatient pharmacist‐led medication reconciliation, coordination of care, postdischarge phone calls, and postdischarge primary care visit.
Study: 32511749
Drug: Tenecteplase 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase 0.4 mg/kg (maximum 40 mg)
Study: 32739102
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BT) intraanal sphincteric injection
Study: 32739102
Drug: Bowel management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel management program (BMP) and senna based laxatives (SBL)
Study: 35278093
Drug: Tät II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tät II treatment focused on pelvic floor muscle training (PFMT) and bladder training (BT)
Study: 39604382
Drug: Traditional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physical therapy program
Study: 33470755
Drug: Transdermal 17-beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17-beta estradiol (TE) 100 mcg/d
Study: 33470755
Drug: Oral raloxifene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral raloxifene 60 mg/d
Study: 33470755
Drug: Proprietary phytoestrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprietary phytoestrogen compound, Rimostil 1000 mg twice/d
Study: 32416181
Drug: Elevated baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated baseline serum uric acid (sUA) levels (>6 mg/dL)
Study: 34817964
Drug: Adhesive/nanofilled resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adhesive/nanofilled resin composite restorations (RC; OptiBond FL, Kerr/Filtek Supreme XTE, 3M Oral Care)
Study: 35505308
Drug: Natremia <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natremia < 135 mmol/L
Study: 33132228
Drug: Dabigatran (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (150 or 110 mg twice daily)
Study: 34410769
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU; n = 133).
Study: 32083994
Drug: Restrictive RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive RBC transfusion strategy (Hb threshold < 70 g/L)
Study: 32083994
Drug: Liberal RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal RBC transfusion strategy (Hb threshold < 90 g/L)
Study: 32088018
Drug: Oral rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rotavirus vaccine (RVV)
Study: 32142484
Drug: C+COX‐2‐Is (convention
Approvals — FDA: no, EMA: no, PMDA: no
Description: C+COX‐2‐Is (convention plus COX‐2 inhibitors)
Study: 37315225
Drug: Any treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any treatment
Study: 32045773
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 1.5 g intra-articular combined with 1.5 g intravenous
Study: 32045773
Drug: Hemocoagulase atrox
Normalized name: Crotalus atrox antivenin
DrugBank: Crotalus atrox antivenin (DB13892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemocoagulase atrox 1 U intra-articular combined with 1 U intravenous
Study: 34049378
Drug: Intravenous somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous somatostatin plus rectal indomethacin (100 mg suppository)
Study: 34049378
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (rectal indomethacin only)
Study: 34268406
Drug: High-dose octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose octreotide
Study: 32460818
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin and co-amoxiclav for at least 5 days after switching from intravenous antibiotics within 12-24 hours of starting IV therapy.
Study: 32460818
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics (piperacillin/tazobactam or meropenem) continued for at least 48 hours.
Study: 36344005
Drug: Restrictive oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive oxygen strategy (lowest dosage of oxygen >21% to ensure SpO2 of 94%)
Study: 36344005
Drug: Liberal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal oxygen strategy (12-15 L O2/min or FiO2 = 0.6-1.0)
Study: 32967392
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard pain management drugs)
Study: 35988198
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment + BAL
Study: 35988198
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment + ST + BAL
Study: 35988198
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment + ST
Study: 33370739
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese music therapy
Study: 33370739
Drug: Painting therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Painting therapy
Study: 35677742
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D therapy requirement
Study: 36058207
Drug: Advanced Hybrid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced Hybrid Closed Loop (AHCL) therapy
Study: 36058207
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections of insulin plus isCGM
Study: 36058207
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections of insulin plus isCGM group
Study: 36395746
Drug: Killed oral
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Killed oral cholera vaccine (OCV) with a second dose after 2 weeks
Study: 36395746
Drug: Killed oral
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Killed oral cholera vaccine (OCV) with a second dose after 6 months
Study: 36395746
Drug: Killed oral
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Killed oral cholera vaccine (OCV) with a second dose after 11.5 months
Study: 34209004
Drug: Suspension training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension training (n = 12)
Study: 34504284
Drug: rTMS (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTMS (20 Hz, 1800 pulses per session) for 4 weeks before lower limb resistance training or physical therapy
Study: 33754424
Drug: Levobupivacaine HCl
Normalized name: LEVOBUPIVACAINE HCL
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levobupivacaine HCl (5.0 mg/mL) mixed with isotonic solution (4, 6, 8, and 10 mL of levobupivacaine with 26, 24, 22, and 20 mL of isotonic solution, respectively)
Study: 33754424
Drug: Levobupivacaine HCl
Normalized name: LEVOBUPIVACAINE HCL
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levobupivacaine HCl (5.0 mg/mL) mixed with isotonic solution
Study: 33754424
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group using Cathejell-2% lidocaine (25 mg lidocaine)
Study: 34102783
Drug: Intranasal glucocorticoid
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal glucocorticoid (dexamethasone) after nasal endoscopic surgery
Study: 34102783
Drug: Oral glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucocorticoid (prednisone) one week before operation and three weeks after operation
Study: 34503552
Drug: Autologous hematopoietic
Normalized name: Autologous Hematopoietic Peripheral Blood Stem Cells
DrugBank: Autologous Hematopoietic Peripheral Blood Stem Cells (DB17067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous hematopoietic stem cell transplant (AHSCT) treatment
Study: 34503552
Drug: Modifiable factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modifiable factors (distance to treatment center and cost)
Study: 36145115
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of ground raw golden flaxseed
Study: 33120302
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of haloperidol and ketamine
Study: 34480579
Drug: Daridorexant 100
Normalized name: Daridorexant
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daridorexant 100 mg
Study: 39641404
Drug: Daridorexant (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daridorexant (both doses)
Study: 36295519
Drug: High-dose intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intramuscular vitamin D (cholecalciferol 200,000 IU)
Study: 36295519
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (alfacalcidol 1 mcg/day)
Study: 33468283
Drug: Behaviourally focused
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviourally focused nutrition education intervention (weekly sessions for 12 weeks)
Study: 33990993
Drug: Anti-cancer drugs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-cancer drugs
Study: 33990993
Drug: Conventional standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional standard therapies
Study: 32241810
Drug: 30 mL/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL/kg/day feed advancement
Study: 32241810
Drug: 18 mL/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mL/kg/day feed advancement (control)
Study: 36217901
Drug: RP7214 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP7214 single dose (100, 200, and 400 mg QD)
Study: 36217901
Drug: RP7214 multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP7214 multiple doses (200 and 400 mg BID for 7 days)
Study: 36217901
Drug: RP7214 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP7214 single dose (200 mg) food effect study
Study: 34192893
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg for 3.3 years
Study: 35106590
Drug: HP501 (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP501 (45 mg) administered over 10 days to hyperuricemic patients
Study: 35106590
Drug: HP501 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP501 (doses from 5 to 60 mg)
Study: 35106590
Drug: HP501 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP501 and febuxostat combination
Study: 35106827
Drug: Non-anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-anticoagulant therapy in patients with AF
Study: 33106609
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin treatment
Study: 33106609
Drug: Standard statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard statin treatment
Study: 35857716
Drug: Amphetamine Extended-Release
Normalized name: amphetamine Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine Extended-Release Tablets (AMPH ER TAB) 5 mg starting dose, increased to 20 mg for 14±3 days before visit 5.
Study: 33956056
Drug: Dapirolizumab pegol
Normalized name: Dapirolizumab pegol
DrugBank: Dapirolizumab pegol (DB16131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapirolizumab pegol (DZP) 6/24/45 mg/kg
Study: 34784941
Drug: Propofol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.5 mg/kg)
Study: 32995892
Drug: Exenatide (EX)
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide (EX) 10-20μg daily
Study: 32995892
Drug: Combination (COM)
Normalized name: CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (COM) of Exenatide and Metformin
Study: 32995892
Drug: Metformin (MET)
Normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (MET) 1500-2000 mg daily
Study: 35910353
Drug: Ivermectin/albendazole 18/400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin/albendazole 18/400 mg (1 tablet)
Study: 35910353
Drug: Ivermectin 3
Normalized name: ivermectin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 3 mg (6 tablets)
Study: 35910353
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg (1 tablet)
Study: 32705834
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Jingui Shenqi pills and Suoquan capsules
Study: 36297036
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg of p-synephrine
Study: 33390295
Drug: COVID-19 vaccine
Normalized name: COVID-19 VACCINE
DrugBank: VidPrevtyn Beta (DB16427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 vaccine approval announced one week before the presidential election
Study: 33390295
Drug: COVID-19 vaccine
Normalized name: COVID-19 VACCINE
DrugBank: VidPrevtyn Beta (DB16427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 vaccine approval announced one week after the presidential election
Study: 33390295
Drug: Endorsement by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endorsement by Dr. Anthony Fauci with pre-election vaccine approval
Study: 33389320
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral pre-exposure prophylaxis and adherence support
Study: 35334049
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (pH 6.0)
Study: 33719503
Drug: Speech Intelligibility
Normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Speech Intelligibility Treatment (SIT)
Study: 33719503
Drug: Hand‐Arm Bimanual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand‐Arm Bimanual Intensive Therapy Including Lower Extremities (PT)
Study: 32343977
Drug: Antireflux ablation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antireflux ablation therapy (ARAT)
Study: 32525464
Drug: Individualized blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized blood pressure lowering treatment
Study: 32417382
Drug: IV Brivaracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Brivaracetam 100 mg
Study: 32417382
Drug: IV Brivaracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Brivaracetam 200 mg
Study: 35352835
Drug: Anifrolumab 300
Normalized name: ANIFROLUMAB 300 mg in 2.0 mL INTRAVENOUS INJECTION, SOLUTION [SAPHNELO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anifrolumab 300 mg Q4W
Study: 35352835
Drug: Anifrolumab 150
Normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anifrolumab 150 mg Q4W
Study: 33496122
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine formula (CHMF)
Study: 34215216
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) treatment for 12 weeks (transcranial, intranasal, neck and abdominal)
Study: 34215216
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment with PBM devices after initial 12 weeks
Study: 34665890
Drug: Oral THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral THC 7.5 mg
Study: 34665890
Drug: Oral THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral THC 15 mg
Study: 34903493
Drug: Lidocaine injection
Normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine injection and oral citalopram
Study: 34903493
Drug: Lidocaine injection
Normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine injection and oral placebo
Study: 34903493
Drug: Injective and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injective and oral placebo
Study: 33063461
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT) using 980 nm diode laser at 0.1 W output power, energy density of 4 J/cm2 delivered at six sites for 10 seconds each
Study: 33063461
Drug: No adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjunctive treatment (Control Group)
Study: 33128912
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g intravenous over 10 min followed by 1 g over 8 h)
Study: 34726958
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg once daily for 24 months)
Study: 34726958
Drug: Cisplatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (80 mg/m2 on day 1) plus Vinorelbine (25 mg/m2 on days 1 and 8; cis/vin) once every 3 weeks for four cycles
Study: 32891163
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 4 IU/d on day 2 of the previous menstrual cycle until the trigger day
Study: 35089613
Drug: Mirtazapine (MZ)
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirtazapine (MZ) 15–45 mg/day
Study: 35089613
Drug: Sertraline (ST)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (ST) 25–200 mg/day